Vallabhajosyula Saraschandra, Ya'Qoub Lina, Kumar Vinayak, Verghese Dhiran, Subramaniam Anna V, Patlolla Sri Harsha, Desai Viral K, Sundaragiri Pranathi R, Cheungpasitporn Wisit, Deshmukh Abhishek J, Kashani Kianoush, Barsness Gregory W
Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN 55905, USA.
Division of Pulmonary and Critical Care Medicine, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA.
J Clin Med. 2020 Nov 18;9(11):3702. doi: 10.3390/jcm9113702.
There are limited data on acute myocardial infarction with cardiogenic shock (AMI-CS) stratified by chronic kidney disease (CKD) stages.
To assess clinical outcomes in AMI-CS stratified by CKD stages.
A retrospective cohort of AMI-CS during 2005-2016 from the National Inpatient Sample was categorized as no CKD, CKD stage-III (CKD-III), CKD stage-IV (CKD-IV) and end-stage renal disease (ESRD). CKD-I/II were excluded. Outcomes included in-hospital mortality, use of coronary angiography, percutaneous coronary intervention (PCI) and mechanical circulatory support (MCS). We also evaluated acute kidney injury (AKI) and acute hemodialysis in non-ESRD admissions.
Of 372,412 AMI-CS admissions, CKD-III, CKD-IV and ESRD comprised 20,380 (5.5%), 7367 (2.0%) and 18,109 (4.9%), respectively. Admissions with CKD were, on average, older, of the White race, bearing Medicare insurance, of a lower socioeconomic stratum, with higher comorbidities, and higher rates of acute organ failure. Compared to the cohort without CKD, CKD-III, CKD-IV and ESRD had lower use of coronary angiography (72.7%, 67.1%, 56.9%, 61.1%), PCI (53.7%, 43.8%, 38.4%, 37.6%) and MCS (47.9%, 38.3%, 33.3%, 34.2%), respectively (all < 0.001). AKI and acute hemodialysis use increased with increase in CKD stage (no CKD-38.5%, 2.6%; CKD-III-79.1%, 6.5%; CKD-IV-84.3%, 12.3%; < 0.001). ESRD (adjusted odds ratio [OR] 1.25 [95% confidence interval {CI} 1.21-1.31]; < 0.001), but not CKD-III (OR 0.72 [95% CI 0.69-0.75); < 0.001) or CKD-IV (OR 0.82 [95 CI 0.77-0.87] was predictive of in-hospital mortality.
CKD/ESRD is associated with lower use of evidence-based therapies. ESRD was an independent predictor of higher in-hospital mortality in AMI-CS.
关于按慢性肾脏病(CKD)分期分层的急性心肌梗死合并心源性休克(AMI-CS)的数据有限。
评估按CKD分期分层的AMI-CS的临床结局。
对2005年至2016年期间来自国家住院患者样本的AMI-CS回顾性队列进行分类,分为无CKD、CKD Ⅲ期(CKD-Ⅲ)、CKD Ⅳ期(CKD-Ⅳ)和终末期肾病(ESRD)。排除CKD Ⅰ/Ⅱ期。结局包括住院死亡率、冠状动脉造影的使用、经皮冠状动脉介入治疗(PCI)和机械循环支持(MCS)。我们还评估了非ESRD住院患者的急性肾损伤(AKI)和急性血液透析情况。
在372412例AMI-CS住院患者中,CKD-Ⅲ期、CKD-Ⅳ期和ESRD分别占20380例(5.5%)、7367例(2.0%)和18109例(4.9%)。有CKD的住院患者平均年龄更大,为白人,拥有医疗保险,社会经济阶层较低,合并症更多,急性器官衰竭发生率更高。与无CKD的队列相比,CKD-Ⅲ期、CKD-Ⅳ期和ESRD使用冠状动脉造影的比例较低(分别为72.7%、67.1%、56.9%、61.1%),PCI(分别为53.7%、43.8%、38.4%、37.6%)和MCS(分别为47.9%、38.3%、33.3%、34.2%)(均P<0.001)。AKI和急性血液透析的使用随CKD分期增加而增加(无CKD-38.5%,2.6%;CKD-Ⅲ期-79.1%,6.5%;CKD-Ⅳ期-84.3%,12.3%;P<0.001)。ESRD(校正优势比[OR]为1.25[95%置信区间{CI}为1.21-1.31];P<0.001),但不是CKD-Ⅲ期(OR为0.72[95%CI为0.69-0.75];P<0.001)或CKD-Ⅳ期(OR为0.82[95CI为0.77-0.87])可预测住院死亡率。
CKD/ESRD与基于证据的治疗方法使用较少有关。ESRD是AMI-CS住院死亡率较高的独立预测因素。